Nearly 40% of this year’s Asia-to-West NewCos are aiming at first in class

Asia-to-West NewCos are known for giving Western investors access to assets that have generated clinical data quickly. Less clear is whether the model also delivers genuine innovation, rather than faster access to me-better therapies targeting validated biology.

BioCentury identified at least 13 companies that launched in 1H26 with Western headquarters and assets licensed from Asia, nearly matching the 14 formed in all of 2025...